Psychiatric Genetics

Skip Navigation LinksHome > June 2013 - Volume 23 - Issue 3 > BDNF polymorphism rs11030101 is associated with the efficacy...
Psychiatric Genetics:
doi: 10.1097/YPG.0b013e328360c894
Brief Reports

BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression

Viikki, Merja L.a,c; Järventausta, Kaijad; Leinonen, Esaa,d; Huuhka, Marttid; Mononen, Ninab; Lehtimäki, Terhob; Kampman, Ollia,e

Collapse Box

Abstract

The aim of the present study was to test for a possible association between two brain-derived neurotrophic factor (BDNF) polymorphisms (rs11030101 and rs61888800) and the efficacy of electroconvulsive therapy (ECT) [change in Montgomery–Åsberg Depression Rating Scale (MADRS)]. So far, there are no studies investigating an association between these polymorphisms and the efficacy of ECT. The patient sample included 119 patients with treatment-resistant major depressive disorder who were treated with ECT. BDNF polymorphism rs11030101, but not rs61888800, was associated with a change in the MADRS score. Patients with the TA genotype of rs11030101 were less likely to benefit from ECT compared with patients with the TT genotype (P=0.041). The finding suggests an association between BDNF polymorphism rs11030101 and the efficacy of ECT. Further studies with larger samples will be required to confirm this finding.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.